Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, Chang YI, Du J, Liu Y, Tey SR, Zhang X, Juckett M, Mattison R, Damnernsawad A, Zhang J, Mulloy JC, Zhang J.

J Clin Invest. 2014 Jun;124(6):2762-73. doi: 10.1172/JCI74182. Epub 2014 May 8.

2.

Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.

Zhang J, Ranheim EA, Du J, Liu Y, Wang J, Kong G, Zhang J.

J Biol Chem. 2015 Jul 31;290(31):19093-103. doi: 10.1074/jbc.M115.653154. Epub 2015 Jun 16.

3.

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.

Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS.

Sci Transl Med. 2011 Mar 30;3(76):76ra27. doi: 10.1126/scitranslmed.3001069.

4.

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K.

J Clin Invest. 2013 Jan;123(1):335-9. doi: 10.1172/JCI63193. Epub 2012 Dec 10. Erratum in: J Clin Invest. 2016 Jan;126(1):404.

5.

Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.

Wang J, Kong G, Liu Y, Du J, Chang YI, Tey SR, Zhang X, Ranheim EA, Saba-El-Leil MK, Meloche S, Damnernsawad A, Zhang J, Zhang J.

Blood. 2013 Jun 27;121(26):5203-7. doi: 10.1182/blood-2012-12-475863. Epub 2013 May 17.

6.

RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.

Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, Lambertenghi Deliliers G, Beran M, Onida F.

Clin Cancer Res. 2010 Apr 15;16(8):2246-56. doi: 10.1158/1078-0432.CCR-09-2112. Epub 2010 Apr 6.

7.

Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.

Wang J, Liu Y, Li Z, Du J, Ryu MJ, Taylor PR, Fleming MD, Young KH, Pitot H, Zhang J.

Blood. 2010 Dec 23;116(26):5991-6002. doi: 10.1182/blood-2010-04-281527. Epub 2010 Oct 4.

8.

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.

Gritsman K, Yuzugullu H, Von T, Yan H, Clayton L, Fritsch C, Maira SM, Hollingworth G, Choi C, Khandan T, Paktinat M, Okabe RO, Roberts TM, Zhao JJ.

J Clin Invest. 2014 Apr;124(4):1794-809. doi: 10.1172/JCI69927. Epub 2014 Feb 24.

9.

Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo.

Wang T, Li C, Xia C, Dong Y, Yang D, Geng Y, Cai J, Zhang J, Zhang X, Wang J.

Am J Transl Res. 2015 Oct 15;7(10):1963-73. eCollection 2015.

10.

Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.

Akutagawa J, Huang TQ, Epstein I, Chang T, Quirindongo-Crespo M, Cottonham CL, Dail M, Slusher BS, Friedman LS, Sampath D, Braun BS.

Leukemia. 2016 Jun;30(6):1335-43. doi: 10.1038/leu.2016.14. Epub 2016 Feb 12.

11.

K-RasV14I recapitulates Noonan syndrome in mice.

Hernández-Porras I, Fabbiano S, Schuhmacher AJ, Aicher A, Cañamero M, Cámara JA, Cussó L, Desco M, Heeschen C, Mulero F, Bustelo XR, Guerra C, Barbacid M.

Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16395-400. doi: 10.1073/pnas.1418126111. Epub 2014 Oct 30.

12.

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.

Pérez B, Kosmider O, Cassinat B, Renneville A, Lachenaud J, Kaltenbach S, Bertrand Y, Baruchel A, Chomienne C, Fontenay M, Preudhomme C, Cavé H.

Br J Haematol. 2010 Dec;151(5):460-8. doi: 10.1111/j.1365-2141.2010.08393.x. Epub 2010 Oct 19.

PMID:
20955399
13.

Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.

Chang YI, You X, Kong G, Ranheim EA, Wang J, Du J, Liu Y, Zhou Y, Ryu MJ, Zhang J.

Leukemia. 2015 Sep;29(9):1847-56. doi: 10.1038/leu.2015.85. Epub 2015 Mar 24.

14.

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K.

Blood. 2011 Feb 10;117(6):2022-32. doi: 10.1182/blood-2010-04-280750. Epub 2010 Dec 16.

15.

NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.

Xue L, Pulikkan JA, Valk PJ, Castilla LH.

Blood. 2014 Jul 17;124(3):426-36. doi: 10.1182/blood-2013-12-541730. Epub 2014 Jun 3.

16.

Chronic myelomonocytic leukemia: myeloproliferative variant.

Onida F, Beran M.

Curr Hematol Rep. 2004 May;3(3):218-26. Review.

PMID:
15087071
17.

Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.

Emanuel PD.

Leukemia. 2008 Jul;22(7):1335-42. doi: 10.1038/leu.2008.162. Epub 2008 Jun 12. Review.

PMID:
18548091
18.

PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.

Goodwin CB, Li XJ, Mali RS, Chan G, Kang M, Liu Z, Vanhaesebroeck B, Neel BG, Loh ML, Lannutti BJ, Kapur R, Chan RJ.

Blood. 2014 May 1;123(18):2838-42. doi: 10.1182/blood-2013-10-535104. Epub 2014 Feb 19.

19.

Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.

Barrio S, Gallardo M, Arenas A, Ayala R, Rapado I, Rueda D, Jimenez A, Albizua E, Burgaleta C, Gilsanz F, Martinez-Lopez J.

Br J Haematol. 2013 Jun;161(5):667-76. doi: 10.1111/bjh.12308. Epub 2013 Apr 5.

PMID:
23560534
20.

Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.

Wang J, Liu Y, Li Z, Wang Z, Tan LX, Ryu MJ, Meline B, Du J, Young KH, Ranheim E, Chang Q, Zhang J.

Blood. 2011 Jul 14;118(2):368-79. doi: 10.1182/blood-2010-12-326058. Epub 2011 May 17.

Supplemental Content

Support Center